Figure 4

Cell viability and proliferative capacity of myofibroblasts upon tumor necrosis factor-alpha (TNF-α) treatment. The effect of the cytokine TNF-α (1 and 10 ng/mL) in the presence or absence of the TNF-α inhibitor infliximab (IFX) (10 μg/mL) or the cyclooxygenase inhibitor diclofenac (Diclo) on myofibroblasts was analyzed by using the MTT cell viability assay. Data are representative of nine (Table 1) independently performed TNF-α ± IFX experiments and seven independently performed TNF-α ± diclofenac experiments with four replicate measurements from each individual patient sample (n = 68 for the 'control' and 'TNF-α 10 ng/mL' groups, n = 28 for the 'TNF-α 10 ng/mL+diclofenac' group, and n = 36 for all other groups). Results are plotted as fold changes of the respective samples in the control group according to the paired non-parametric Wilcoxon test used for the statistical analysis. *P < 0.05, ***P < 0.001. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide.